SC Slams Hospital Drug Markups and Urges 16% Price Cap
Scrutiny Over Hospital Drug Markups
The Supreme Court of India recently raised serious alarms over excessive hospital drug markups. Specifically, a bench comprising Justices Vikram Nath and Sandeep Mehta criticized extreme retail price inflation. For example, the judges highlighted a critical cancer medicine with an alarming price difference. Manufacturers supplied this oncology injection for Rs 2,700, yet retailers set the MRP at Rs 27,000. Consequently, the bench described this tenfold price inflation as plain carnage. Moreover, the court noted that high costs directly harm patients and government healthcare schemes, making it essential for medical professionals specializing in clinical oncology to stay informed about drug pricing ethics. As a result, shares of major corporate hospital chains tumbled up to six percent.
Proposed Uniform 16 Percent Margin Cap
The apex court urged the Union government to evaluate uniform price regulations. Therefore, Justice Mehta asked why authorities should distinguish between essential and non-essential formulations. Under the Drugs Prices Control Order 2013, scheduled medicines receive a fixed 16 percent retailer margin. However, non-scheduled drugs currently escape strict retail margin caps. Thus, the court proposed extending this 16 percent limit to all pharmaceutical products. Furthermore, the bench emphasized that taxpayers ultimately bear the financial burden. For instance, public insurance schemes like Ayushman Bharat reimburse these inflated hospital claims. In response, Solicitor General Tushar Mehta requested two weeks to study the issue.
Scrutiny of In-House Hospital Pharmacies
The Supreme Court also examined the controversial practices of private hospital pharmacies. Many healthcare facilities require admitted patients to buy drugs exclusively from in-house counters. In addition, institutions often refuse medications that families purchase from external chemists. The bench strongly questioned who truly profits from these restrictive dispensing rules. Meanwhile, Solicitor General Mehta stated that private hospitals capture the majority of these margins. Consequently, the court warned that commercial hospital operations must not exploit vulnerable families. Additionally, the bench criticized pricing discrepancies between single molecules and fixed-dose combinations. Therefore, these proceedings could soon reshape hospital procurement and retail pharmacy operations nationwide, impacting everyday general practice across the country.
Frequently Asked Questions
Q1: Why did the Supreme Court question hospital drug markups?
The court identified extreme pricing gaps in critical medicines. For example, hospitals sold an oncology injection costing Rs 2,700 for an MRP of Rs 27,000. Consequently, this tenfold markup heavily burdens patients and public funds.
Q2: What did the court propose regarding the DPCO 16 percent margin?
Currently, the DPCO applies a 16 percent retailer margin only to scheduled essential medicines. Therefore, the Supreme Court asked the Centre to examine whether a uniform 16 percent cap should cover all medicines.
Q3: How are in-house hospital pharmacies affected by these proceedings?
The Supreme Court questioned hospital policies that force patients to buy medicines solely from internal counters. Consequently, the government must review these restrictive commercial practices and report back to the court.
References
- Hospital stocks fall as SC questions drug mark-ups - ETHealthworld
- Supreme Court questions steep mark-ups on cancer drugs, calls pricing disparity 'carnage' - The Hindu
- Why Not Cap Medicines' MRPs At 16% Above Retailer Prices? Supreme Court Asks - LiveLaw
